Replies to post #940 on RedHill Biopharma Ltd (RDHL)

[noretreat]

08/15/2017
RHB-104 MAP US
Crohn’s disease
Phase 3 DSMB safety analysis released December 13, 2016 - trial to continue as planned. Interim efficacy analysis due early August 2017 - assume latest possible date is August 15.

09/30/2017
BEKINDA
IBS-D
Phase 2 top-line data due September 2017. Noted July 17, 2017 that last patient has been enrolled.